ARID1A and urinary bladder neoplasm: This mechanistic convergence aligns with recent reports: ARID1A-mutant bladder tumors exhibit higher TMB and improved ICIs outcomes, and a significant increase in CD4+ T-lymphocyte infiltration has been observed in ICIs responders (27).